Pharmacokinetics of enfuvirtide in a patient with impaired renal function.
Enfuvirtide is the first member of the fourth class of antiretroviral drugs to become available. We present a case report of a human immunodeficiency virus (HIV)-positive patient with mild renal impairment who developed severe renal impairment secondary to tenofovir therapy while receiving enfuvirtide. Because the patient's pharmacokinetic profile was not significantly altered, compared with that of HIV-infected patients with normal renal function, no dose modifications were required.
Leen
Clifford
C
Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, United Kingdom. clifford.leen@ed.ac.uk
Wat
Cynthia
C
Nieforth
Keith
K
D000328:Adult; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors / Q000493:pharmacokinetics*; D006679:HIV Seropositivity / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000378:metabolism*; D008297:Male; D010446:Peptide Fragments / Q000493:pharmacokinetics*
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide